Reason for request
Assessment of change of dose permitting use in children aged between 2 and 16.
Clinical Benefit
| Substantial |
The clinical benefit provided by DUROGESIC in children is substantial. |
Clinical Added Value
| Comments without ASMR value |
DUROGESIC has previously been recognised by the Transparency Committee as providing actual benefit in adults, and it provides the same benefit for children over 2. |
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
ESdE3HfcSm6EGNQP
